Ascletis Pharma (HKG:1672) posted promising Phase Ib trial results in the U.S. for ASC30, a potential first-in-class GLP-1 receptor agonist for treating obesity, according to a Monday filing with the Hong Kong bourse.
A single subcutaneous injection of ASC30 showed a 36-day half-life, supporting once-monthly dosing. The oral tablet form of ASC30 also demonstrated "6.3% weight loss in patients with obesity after a four-week treatment."
Ascletis holds global patent protection until 2044 for ASC30.
The pharmaceutical shares were up by 5.8%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.